Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.

Schroeder T, Piantadosi CA, Natoli MJ, Autmizguine J, Cohen-Wolkowieczs M, Hamilton KL, Bell C, Klawitter J, Christians U, Irwin DC, Noveck RJ.

Clin Pharmacol Ther. 2018 May;103(5):888-898. doi: 10.1002/cpt.860. Epub 2017 Oct 17.

2.

Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

Mercurio V, Mukherjee M, Tedford RJ, Zamanian RT, Khair RM, Sato T, Minai OA, Torres F, Girgis RE, Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):388-391. doi: 10.1164/rccm.201704-0789LE. No abstract available.

3.

Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).

Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, Gillies H, Tislow J, Oudiz RJ.

Respir Med. 2017 May;126:84-92. doi: 10.1016/j.rmed.2017.03.025. Epub 2017 Mar 29.

4.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

5.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11.

PMID:
27745818
6.

Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.

Huo Y, Jing ZC, Zeng XF, Liu JM, Yu ZX, Zhang GC, Li Y, Wang Y, Ji QS, Zhu P, Wu BX, Zheng Y, Wang PP, Li J.

BMC Cardiovasc Disord. 2016 Oct 22;16(1):201.

7.

Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.

Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SD.

Respir Med. 2016 Aug;117:254-63. doi: 10.1016/j.rmed.2016.06.018. Epub 2016 Jun 29.

8.

Effect of Ambrisentan on Exercise Capacity in Adult Patients After the Fontan Procedure.

Cedars AM, Saef J, Peterson LR, Coggan AR, Novak EL, Kemp D, Ludbrook PA.

Am J Cardiol. 2016 May 1;117(9):1524-32. doi: 10.1016/j.amjcard.2016.02.024. Epub 2016 Feb 23.

PMID:
27063478
9.
10.

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension.

Hakamata A, Odagiri K, Miyakawa S, Irisawa H, Takeuchi K, Inui N, Tanaka S, Uchida S, Watanabe H.

Clin Transl Sci. 2016 Feb;9(1):29-35. doi: 10.1111/cts.12382. Epub 2016 Jan 12.

11.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

12.

Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.

Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Wells AU, Shao L, Zhou H, Henig N, Szwarcberg J, Gillies H, Montgomery AB, O'Riordan TG.

Eur Respir J. 2015 Nov;46(5):1370-7. doi: 10.1183/13993003.01537-2014. Epub 2015 Aug 6.

14.

The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.

Markert C, Kastner IM, Hellwig R, Kalafut P, Schweizer Y, Hoffmann MM, Burhenne J, Weiss J, Mikus G, Haefeli WE.

Basic Clin Pharmacol Toxicol. 2015 May;116(5):423-8. doi: 10.1111/bcpt.12332. Epub 2014 Nov 8.

15.

Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study.

Chung L, Ball K, Yaqub A, Lingala B, Fiorentino D.

J Am Acad Dermatol. 2014 Aug;71(2):400-1. doi: 10.1016/j.jaad.2014.04.028. No abstract available.

16.

Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.

Zhuang Y, Jiang B, Gao H, Zhao W.

Hypertens Res. 2014 Jun;37(6):507-12. doi: 10.1038/hr.2014.28. Epub 2014 Mar 20.

PMID:
24646647
18.

[Efficacy and safety of ambrisentan therapy in Chinese patients with pulmonary hypertension].

Chen FD, Zhou DX, Di RM, Zou Y, Wei W, Liu XB.

Zhonghua Yi Xue Za Zhi. 2013 Sep 10;93(34):2736-8. Chinese.

PMID:
24360110
19.

[Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients].

He J, Wen L, Jiang R, Zhao QH, Wang L, Jiang X, Yan P, Bai L, Jing ZC.

Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Jun;41(6):493-6. Chinese.

PMID:
24113042
20.

Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).

Maron BA, Waxman AB, Opotowsky AR, Gillies H, Blair C, Aghamohammadzadeh R, Loscalzo J, Leopold JA.

Am J Cardiol. 2013 Sep 1;112(5):720-5. doi: 10.1016/j.amjcard.2013.04.051. Epub 2013 Jun 7.

Supplemental Content

Loading ...
Support Center